BRAF mutations were addressed in depth this year, having been mentioned in 3 of this year’s top 5 articles. Also discussed were a first-in-its-class combination treatment approval and potential indicators of increased skin cancer risk.
BRAF mutations were addressed in depth this year on AJMC.com’s skin cancer page, having been mentioned in 3 of this year’s top 5 articles. Also discussed were a first-in-its-class combination treatment approval and potential indicators of increased skin cancer risk.
Here are the top 5 most-read skin cancer articles of 2022.
5. Dr Sigrun Hallmeyer Highlights Clinical Achievements and Barriers in Melanoma
In this interview with Sigrun Hallmeyer, MD, medical director of Advocate Lutheran General Hospital’s Cancer Service Line and codirector of medical research at Advocate Aurora Health, in Illinois, she addresses several important topics regarding melanoma. Chief among them are top goals for treating patients with advanced disease, the impact of social determinants of health on patient outcomes, and the effects of payer decisions regarding coverage, diagnosis, and treatment. Treatment resistance and cancer survivorship are also discussed.
4. Dabrafenib Plus Trametinib Approved as First Tumor-Agnostic Therapy for BRAF V600E–Mutated Solid Tumors
Adult and pediatric patients who have solid tumors with a BRAF V600E mutation received good news in June with the FDA’s approval of the combination treatment, the first therapy to be approved by the agency for a tumor-agnostic indication in these patient populations. Accounting for up to 90% of BRAF-mutant cancers, the indication for BRAF V600E came after dabrafenib plus trametinib demonstrated safety and efficacy in 3 clinical trials: for adults, the phase 2 Rare Oncology Agnostic Research and the NCI-MATCH Subprotocol H studies, and for children, Study X2101.
3. Neurofibromatosis Type 1 Linked to Greater Skin Cancer Risk
Risks for basal cell carcinoma (BCC), squamous cell carcinoma (SCC), keratinocyte carcinoma (KC), and melanoma were higher among a cohort of patients who lacked neurofibromin, a tumor suppressor gene. Not having this gene can lead to the development of benign skin, eye, and nervous system tumors and a potentially higher risk of nervous system or other solid organ cancers. The risk for BCC was 30% higher; SCC, 32%; KC, 31%; and melanoma, 127%. A subanalysis of outcomes among patients of various ethnicities found that Hispanic patients and Black patients had the highest risks of KC vs comparable risk among White patients and Asian patients.
2. Dr Martin Dietrich Describes Need to Move Quickly With “Aggressive, Unpredictable” Melanoma
In this interview, Martin Dietrich, MD, PhD, of Florida Cancer Specialists, discusses melanoma risk factors, genomic testing, and the importance of prompt action—because melanoma is known for rapidly advancing. Dietrich also addresses the impact that the BRAF V600E mutation can have in the space, as well as non-V600 mutations, and goes into detail about potential longer-term benefits from sequencing targeted therapy then immunotherapy instead of immunotherapy and then targeted treatment. He closes with an in-depth discussion on melanoma disease management considerations, noting that immunotherapy comes with certain long-term consequences but is often the default treatment because “of the simplicity” and more discussions need to be held around how to manage patients with locally advanced metastatic melanoma.
1. ctDNA Accurately Detects BRAF Mutations in Advanced Melanoma, Study Finds
With advantages that include minimal invasiveness, low cost, reproducibility, and shortened wait times for results, liquid biopsy via analysis of circulating tumor DNA (ctDNA) was shown in this March piece to “be a viable option for determining the presence of BRAF mutations in patients with advanced melanoma.” With tissue samples often difficult to obtain when wanting to assess BRAF mutation status, the study authors highlighted that liquid biopsy is considered a simpler option, even though a majority of its use takes place in clinical trials and research settings—so that wider use remains very limited.
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Federated Learning Models Show Potential in Melanoma-Nevus Classification, but Improvements Needed
March 16th 2024A multicentric, single-arm diagnostic study created a decentralized federated learning model for the classification of invasive melanomas and nevi, showcasing comparable results to centralized data models.
Read More